Trial · NCT01713582
Results by group138
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 138
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) | AL 10 mg QD 14-21 | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | AL 20 mg QD 14-21 | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | AL 40 mg QD 14-21 | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | AL 20 mg BID 21-21 | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | AL 80 mg QD 14-21 | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | AL 40 mg BID 14-21 | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | AL 120 mg QD 14-21 | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | AL 120 mg QD 21-21 | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | AL 160 mg QD 14-21 | 2 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | AML de Novo 80 mg QD 14-21 | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | AML/MDS 80 mg QD 14-21 | 1 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | OHM 10 mg QD 21-21 | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | OHM 20 mg QD 21-21 | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | OHM 40 mg QD 21-21 | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | OHM 80 mg QD 21-21 | 2 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | OHM 40 mg BID 21-21 | 5 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | OHM 120 mg QD 21-21 | 4 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | OHM 120 mg QD 14-21 | 2 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | OHM 120 mg QD 5-7 | 3 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) | OHM 120 mg QD 7-21 | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01713582/results